Esperion Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Product
Collaboration Revenue
Total Revenues
Operating expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Total operating expenses
Income (loss) from operations
Interest expense
Loss on extinguishment of debt and exchange transaction
Other income, net
Loss before income taxes
Provision for taxes on income
Net loss
Net loss per common share - basic (in dollars per share)
Net loss per common share - diluted (in dollars per share)
Weighted-average shares outstanding - basic (in shares)
Weighted-average shares outstanding - diluted (in shares)
Other comprehensive (loss) gain:
Unrealized gain on investments
Total comprehensive loss

Comments